about
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cellsThe effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaIdarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemiaSeed Oil of Brucea javanica Induces Apoptotic Death of Acute Myeloid Leukemia Cells via Both the Death Receptors and the Mitochondrial-Related PathwaysTargeting mTOR for the treatment of AML. New agents and new directionsDefining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesPI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical applicationHeparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor in normal and neoplastic hematopoiesisOxidative stress responses and NRF2 in human leukaemiaCombined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemiaMetabolomic profiling of drug responses in acute myeloid leukaemia cell linesBone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosisAKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinDasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacityPterostilbene simultaneously induced G0/G1-phase arrest and MAPK-mediated mitochondrial-derived apoptosis in human acute myeloid leukemia cell linesFunctional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone CompoundDistinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemiaAnalysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3.Imaging findings in recurrent extramedullary leukaemias.Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.A look to future directions in gene therapy research for monogenic diseases.Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells.A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemiaTargeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.Glabridin mediate caspases activation and induces apoptosis through JNK1/2 and p38 MAPK pathway in human promyelocytic leukemia cells.Targeted regulation of MiR-98 on E2F1 increases chemosensitivity of leukemia cells K562/A02.Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical designChallenges in treating older patients with acute myeloid leukemia.Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasVoreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.Leukemia regression by vascular disruption and antiangiogenic therapy.
P2860
Q21245461-40ACAC94-73EA-4593-A759-308397F15A23Q24187297-285397B7-2A9D-4927-AC74-A0EF5B0D7769Q24200407-DE848967-20BF-422B-88B4-5FF8510FBE56Q24594585-547ED2C8-9C64-4AAF-80AE-965D4E3707E0Q24617223-D21435F6-72EF-4303-979E-66E3B96F0125Q26772235-05A7C2F1-FF9F-4CD4-9D3B-5A6ACEA21553Q26801538-30897B34-3B93-40C4-A15E-10FC5D713C97Q26852845-504ABEFD-96AC-4A2C-AC4C-8C68E655232CQ26864239-8AEFAF60-7CB0-4989-8C05-E965CCC62257Q28472176-A88E3D2C-B27F-4A3A-AD5D-9E9D218EFA83Q28474545-FA33FE2B-C55C-4FD6-8DD7-AA08214E34E5Q28483881-1285208A-5424-499C-8B75-A6B6420648E3Q28484890-7EDD5A28-D354-4F02-BF08-95ED108A1625Q28539582-76F9A5CD-F472-4711-944B-153881B42258Q28542481-8FD1F282-0B63-4DFB-AA47-B8ED2CE08CECQ28546856-B7DCA1CC-58B7-4A0F-88CA-188186A4D0DFQ28547905-A89DD2F1-0E9B-46A5-A086-72EE133D21AEQ28749564-092AE9C6-C907-479D-B744-547FEC2852F0Q30396832-BE1A9B5D-DB0D-4F54-A025-204FBDFA538CQ30436744-67DA1733-B645-458D-9501-F493A9AE8FD2Q30976460-17B5FC49-CD4E-432E-9088-BD7626730432Q33258821-BFF76968-79CF-4D4E-9CB6-615BD6531376Q33320806-D521B5CF-2A59-4855-98B5-C842EAF0CB3DQ33392683-58687F04-2129-4C14-9344-77137B499A28Q33406770-5D608239-2EA7-4623-8C84-A2900CBA5433Q33491557-B8BA7E81-0237-48BC-9F26-6E7E0D8DF684Q33493174-41381DAA-A264-48CF-B5A6-FD0BFE698436Q33515031-8D27F19D-F73A-46F2-BC02-7537345AB38BQ33684432-312DC022-7B1C-4C77-8BC7-6C55190DCCB2Q33717069-F47198C8-B4CE-4FD6-98E9-E6F59A9F6F1AQ33879017-774A2583-FE08-48A1-BA49-CD82F83F8793Q33882849-484845E9-9C81-4C1F-8DD2-02F777B51039Q33906004-217554DB-4544-4B3E-8789-78F3F416C825Q33934665-60CDF02B-4B60-4A74-92D6-575C7AC01B8CQ33985549-92687C5A-E724-4668-98D0-121175531176Q34047994-34C22953-237C-41E2-B853-78E59152C6F1Q34052352-9B08522E-A82B-4751-8FC3-27DDE2779A03Q34063343-86ACE8F1-4854-47BD-BEDE-CC5AE26A0CF6Q34063560-95EE827A-56A7-4D57-9D77-561210BAC996Q34124965-A3D8B913-EBF3-4EED-A630-3AB0E6FB09FE
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Drug therapy for acute myeloid leukemia.
@ast
Drug therapy for acute myeloid leukemia.
@en
type
label
Drug therapy for acute myeloid leukemia.
@ast
Drug therapy for acute myeloid leukemia.
@en
prefLabel
Drug therapy for acute myeloid leukemia.
@ast
Drug therapy for acute myeloid leukemia.
@en
P1433
P1476
Drug therapy for acute myeloid leukemia.
@en
P2093
D Gary Gilliland
Jacob M Rowe
P304
P356
10.1182/BLOOD-2005-01-0178
P407
P577
2005-05-03T00:00:00Z